Milliman Secures Japan’s Second Private Sector Certification for Pseudonymized Medical Data Use
Event summary
- Milliman obtained Type II certification as a 'Certified Pseudonymized Medical Information User' in Japan under the Next Generation Medical Infrastructure Act.
- The certification enables secure use of pseudonymized medical data, including rare disease information that would otherwise require anonymization or deletion.
- Milliman’s healthcare practice in Tokyo will leverage this for pharmaceutical and medical device research, cost-effectiveness studies, and policy recommendations.
- Kosuke Iwasaki, Leader of Milliman’s healthcare Practice in Tokyo, emphasized the certification’s role in enhancing evidence-based decision-making.
The big picture
Milliman’s certification underscores the growing importance of pseudonymized medical data in Japan, where stricter regulations aim to balance data utility with privacy. This move aligns with broader trends in health economics and outcomes research, where real-world data is increasingly critical for evidence-based decision-making. The certification positions Milliman as a key player in a niche but expanding market segment.
What we're watching
- Data Utilization Expansion
- How Milliman will integrate pseudonymized data with existing anonymized datasets to enhance research quality and client offerings.
- Regulatory Compliance
- Whether the certification will accelerate similar certifications among other private firms in Japan’s healthcare sector.
- Market Differentiation
- The pace at which Milliman can translate this certification into tangible advantages over competitors in pharmaceutical and medical device consulting.